Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

BRCA2 hypomorphic missense variants confer moderate risks of breast cancer

  • kConFab/AOCS Investigators
  • , NBCS Collaborators
  • Mayo Clinic Rochester, MN
  • Leiden University
  • Institut Curie
  • The University of Chicago
  • University of Utah School of Medicine
  • Helsinki University Hospital
  • Samuel Lunenfeld Research Institute
  • University of Toronto
  • University of California, Irvine
  • German Cancer Research Center
  • Friedrich-Alexander University Erlangen-Nürnberg
  • Centro de Investigación en Red de Enfermedades Raras
  • Centre for Biomedical Research on Rare Diseases (CIBERER)
  • Hannover Medical School
  • Copenhagen University Hospital – Herlev and Gentofte
  • University of Copenhagen
  • University of Cambridge
  • Oslo University Hospital-Radiumhospitalet
  • University of Oslo
  • Robert Bosch Foundation
  • University of Tübingen
  • International Agency for Research on Cancer
  • Antoni van Leeuwenhoek Hospital
  • University Hospitals Leuven
  • Ruhr University Bochum
  • Heidelberg University 
  • University of Hamburg
  • Queensland Institute of Medical Research
  • National University of Singapore
  • Seoul National University
  • Erasmus University Rotterdam
  • University of Sheffield
  • Karolinska Institutet
  • London School of Hygiene and Tropical Medicine
  • University of California at Los Angeles
  • University of Edinburgh
  • National Cancer Institute (NCI)
  • Cancer Council Victoria
  • Melbourne School of Population and Global Health
  • Occupational and Social Determinants of Health
  • Keck School of Medicine of USC
  • MOH Holdings Pte Ltd.
  • Erasmus MC Cancer Institute
  • Aichi Cancer Center Hospital and Research Institute
  • Nagoya University
  • Pomeranian Medical University in Szczecin
  • University of Eastern Finland
  • Oslo University Hospital
  • Sime Darby Medical Centre
  • University of Malaya
  • Vesalius Research Center
  • KU Leuven
  • University of Hawai'i at Mānoa
  • University of Warwick
  • Masaryk Memorial Cancer Institute
  • Cyprus Institute of Neurology and Genetics
  • University of Manchester
  • Beckman Research Institute of City of Hope
  • University of Groningen
  • FIRC Institute of Molecular Oncology
  • University of Oulu
  • Northern Finland Laboratory Centre Oulu
  • IRCCS Fondazione Istituto Nazionale per lo studio e la cura dei tumori - Milano
  • Shaukat Khanum Memorial Cancer Hospital and Research Centre
  • The National Cancer Institute
  • Guy’s Hospital
  • Institute of Cancer Research
  • China Medical University Taichung
  • Academia Sinica - Institute of Biomedical Sciences
  • Vanderbilt University
  • University of Melbourne
  • University of Oxford
  • National Taiwan University Hospital
  • Shanghai Municipal Center for Disease Control and Prevention
  • The University of Sydney
  • University of Otago
  • Demokritos National Centre for Scientific Research
  • Ghent University
  • Liguria Cancer Registry c/o IST/UNIGE
  • H. Lee Moffitt Cancer Center & Research Institute
  • University of South Florida, Tampa
  • University of Utah

Producción: Contribución a una revistaArtículorevisión exhaustiva

77 Citas (Scopus)

Resumen

Breast cancer risks conferred by many germline missense variants in the BRCA1 and BRCA2 genes, often referred to as variants of uncertain significance (VUS), have not been established. In this study, associations between 19 BRCA1 and 33 BRCA2 missense substitution variants and breast cancer risk were investigated through a breast cancer case-control study using genotyping data from 38 studies of predominantly European ancestry (41,890 cases and 41,607 controls) and nine studies of Asian ancestry (6,269 cases and 6,624 controls). The BRCA2 c.9104A>C, p.Tyr3035Ser (OR = 2.52; P = 0.04), and BRCA1 c.5096G>A, p.Arg1699Gln (OR = 4.29; P = 0.009) variant were associated with moderately increased risks of breast cancer among Europeans, whereas BRCA2 c.7522G>A, p.Gly2508Ser (OR = 2.68; P = 0.004), and c.8187G>T, p.Lys2729Asn (OR = 1.4; P = 0.004) were associated with moderate and low risks of breast cancer among Asians. Functional characterization of the BRCA2 variants using four quantitative assays showed reduced BRCA2 activity for p.Tyr3035Ser compared with wild-type. Overall, our results show how BRCA2 missense variants that influence protein function can confer clinically relevant, moderately increased risks of breast cancer, with potential implications for risk management guidelines in women with these specific variants.

Idioma originalInglés
Páginas (desde-hasta)2789-2799
Número de páginas11
PublicaciónCancer Research
Volumen77
N.º11
DOI
EstadoPublicada - 01 jun 2017

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

  1. ODS 3: Salud y bienestar
    ODS 3: Salud y bienestar

Huella

Profundice en los temas de investigación de 'BRCA2 hypomorphic missense variants confer moderate risks of breast cancer'. En conjunto forman una huella única.

Citar esto